Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Value Fund median (27 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 02 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | UTI Value Fund |
|---|---|
| 02 Jan 2013 | ₹100.00 |
| 21 Feb 2014 | ₹103.72 |
| 12 Apr 2015 | ₹147.74 |
| 31 May 2016 | ₹119.08 |
| 19 Jul 2017 | ₹133.48 |
| 07 Sep 2018 | ₹148.49 |
| 27 Oct 2019 | ₹135.23 |
| 15 Dec 2020 | ₹168.14 |
| 03 Feb 2022 | ₹231.25 |
| 25 Mar 2023 | ₹222.17 |
| 12 May 2024 | ₹321.64 |
| 01 Jul 2025 | ₹395.43 |
| 20 Aug 2026 | ₹391.77 |
| Metric | UTI · Direct · IDCW NAV ₹60.25 Very High risk ★★★☆☆ | Category median Value Fund · 27 funds |
|---|---|---|
| -0.39% | +2.79% | |
| +14.63% | +12.68% | |
| +12.87% | +11.98% | |
| +11.82% | +10.69% | |
| +10.54% | +11.75% | |
| +12.05% | — | |
| +11.47% | +13.57% | |
| +11.38% | +12.46% | |
| +11.10% | +12.08% | |
| Risk | ||
| 13.38% | 14.87% | |
| 0.61 | 0.40 | |
| 0.84 | 0.54 | |
| -37.75% | -37.93% | |
| Nifty 500 | — | |
| +2.40% | +0.85% | |
| 0.94 | 0.95 | |
| 103.3% | 102.9% | |
| 91.1% | 102.9% | |
| 1.22% | 1.20% | |
| ₹9,346Cr | ₹1,405Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 13% | 40% | |
| Amit Premchandani | — | |
| 02 Jan 2013 | — | |
| 62 | — | |
| 41.3% | — | |
| 0.5% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.